Drug intelligence / Profile preview

GTP-201

Development stage: Preclinical
Lead developer: Passage Bio
Modality: Gene Therapies

Overview

GTP-201 is an adeno-associated virus (AAV)-delivered gene therapy candidate being developed for the treatment of Frontotemporal dementia. It was licensed by Passage Bio from the University of Pennsylvania's Gene Therapy Program (GTP) in February 2019. Under this agreement, GTP is responsible for preclinical development, while Passage Bio manages clinical development, regulatory affairs, manufacturing, and commercialization.

Beyond the preview

Go deeper on GTP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTP-201.

Explore the full profile